search
Back to results

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

Primary Purpose

Influenza

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
non-elderly aged between 18 and 60
elderly aged over 60
Sponsored by
Adimmune Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza focused on measuring influenza, vaccine, immunogenicity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Males or non-pregnant females and aged ≥ 18 years;
  • Willing and able to adhere to visit schedules and all study requirements;
  • Subjects read and signed the study-specific informed consent.

Exclusion Criteria:

  • Subject or his/her family is employed by the participated hospital;
  • Subjects received 2010-2011 seasonal influenza vaccine within the previous 6 months;
  • History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication
  • Personal or family history of Guillain-Barré Syndrome
  • An acute febrile illness within 1 week prior to vaccination;
  • Current upper respiratory illness, including the common cold or nasal congestion within 72 hours
  • Subjects with influenza-like illness as defined by the presence of fever (temperature ≥ 38°C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough
  • Female subjects who are pregnant during the study
  • Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent
  • Immunodeficiency, or under immunosuppressive treatment
  • Receipt of any vaccine within 1 week prior to study vaccination or expected receipt between Visit 1 (study vaccination) and Visit 2 (final collection of blood samples);
  • Receipt of any blood products, including immunoglobulin in the prior 3 months;
  • Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine

Sites / Locations

  • National Cheng Kung University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AdimFlu-S 2011-2012

Arm Description

Outcomes

Primary Outcome Measures

The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 40.
Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI).

Secondary Outcome Measures

Full Information

First Posted
August 5, 2011
Last Updated
July 10, 2012
Sponsor
Adimmune Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01411358
Brief Title
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects
Official Title
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2011-2012, in Non-Elderly Adult and Elderly Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adimmune Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HAI) at 21 days post immunization in non-elderly and elderly subjects in compliance with the requirements of the current European Union (EU) recommendations for the evaluation of the immunogenicity for a new formulation of a licensed flu vaccine (CPMP/BWP/214/96).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
influenza, vaccine, immunogenicity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
128 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AdimFlu-S 2011-2012
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
non-elderly aged between 18 and 60
Intervention Description
one dose of 0.5mL AdimFlu-S
Intervention Type
Biological
Intervention Name(s)
elderly aged over 60
Intervention Description
one dose of 0.5mL AdimFlu-S
Primary Outcome Measure Information:
Title
The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 40.
Description
Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI).
Time Frame
3 weeks post vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males or non-pregnant females and aged ≥ 18 years; Willing and able to adhere to visit schedules and all study requirements; Subjects read and signed the study-specific informed consent. Exclusion Criteria: Subject or his/her family is employed by the participated hospital; Subjects received 2010-2011 seasonal influenza vaccine within the previous 6 months; History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication Personal or family history of Guillain-Barré Syndrome An acute febrile illness within 1 week prior to vaccination; Current upper respiratory illness, including the common cold or nasal congestion within 72 hours Subjects with influenza-like illness as defined by the presence of fever (temperature ≥ 38°C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough Female subjects who are pregnant during the study Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent Immunodeficiency, or under immunosuppressive treatment Receipt of any vaccine within 1 week prior to study vaccination or expected receipt between Visit 1 (study vaccination) and Visit 2 (final collection of blood samples); Receipt of any blood products, including immunoglobulin in the prior 3 months; Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gin-Hsiang Wu, MD
Organizational Affiliation
National Cheng-Kung University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cheng Kung University Hospital
City
Tainan
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

We'll reach out to this number within 24 hrs